19.4Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.
n/a = not applicable AbbVie Inc.
Consolidated Statements of Earnings
Quarter and Nine Months Ended September 30, 2013 and 2012
(Unaudited) (In millions, except per share data)Third Quarter Ended September 30Nine Months Ended
September 302013201220132012Net sales
$4,658$4,508$13,679$13,174Cost of products sold
1,0921,0143,2993,243Selling, general and administrative
1,2611,0853,9043,578Research and development
7148132,0572,097Acquired in-process research and development
220--290260Total operating cost and expenses
1,3711,5964,1293,996Interest (income) expense, net
69(1)210(4)Net foreign exchange (gain) loss
1164027Other (income) expense, net
5(13)(14)(39)Earnings before income tax
1,2861,6043,8934,012Income tax expense
$964$1,585$3,000$3,735Diluted earnings per share
$0.60$1.01$1.86$2.37Average diluted shares outstanding1,6051,5771,6021,577Note: On Jan. 1, 2013, Abbott Laboratories distributed 1,577 million shares of AbbVie common stock to Abbott's shareholders in connection with the separation of AbbVie from Abbott. The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2012 was calculated using the shares distributed on Jan. 1, 2013. AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended September 30, 2013
(Unaudited) (In millions, except per share data)1. Specified items impacted results as follows:3Q13Earnings
Copyright©2012 PR Newswire.
All rights reserved